Additionally, obesity‐induced changes in immune cells, such as increased PD‐1 expression on T cells and TAMs, create a unique immune microenvironment that paradoxically improves the efficacy of checkpoint inhibition therapy (Figure 5). The gene discussed is PDCD1; the disease is obesity due to melanocortin 4 receptor deficiency.